Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Aligos Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0
6.19
3.61
2.19
Research and development
44
79.9
104
85.1
73
70.3
69.5
General and administrative
10
17.9
28.5
26.4
30.6
22.8
20.7
Operating expenses
54
97.8
133
111
104
93.1
90.2
Operating income
-54
-97.8
-128
-97.6
-88.1
-89.2
-88
Pre-tax income
-52.2
-108
-128
-95.9
-86.9
-131
-23.9
Income tax
0.09
0.16
0.14
0.11
0.8
0.33
0.31
Net income
-52.3
-109
-128
-96
-87.7
-131
-24.2
EBITDA
-52.6
-95.1
-125
-95.3
-86.6
-88.1
-87.1
EPS, basic
-654.83
-273.35
-80.97
-56.58
-34.20
-20.94
-2.45
EPS, diluted
-654.83
-273.35
-80.97
-56.58
-34.20
-20.94
-2.45
Shares, basic (weighted)
0.08
0.4
1.58
1.7
2.56
6.26
9.88
Shares, diluted (weighted)
0.08
0.4
1.58
1.7
2.56
6.26
9.88
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
69.6
220
187
81.3
136
37
18.3
Short-term investments
48.1
23.1
3.92
44.5
19.9
59.5
Other current assets
2.03
5.94
13.5
7.6
5.31
5.09
4.91
Total current assets
120
250
204
134
141
62.1
82.9
Property, plant and equipment
8.52
8.01
6.18
4.82
3.26
2.36
1.87
Lease right-of-use assets
7.57
6.9
8.79
7.7
6.56
4.96
3.09
Long-term investments
10
15.1
Other non-current assets
0.19
0.38
0.87
0.63
0.63
0.63
0.72
Total assets
147
265
235
147
152
70.1
88.5
Accounts payable
3.77
3.31
3.02
4.74
2.52
2.57
3.98
Accrued liabilities
7.6
16.6
25.4
16
16.8
15.6
13.5
Deferred revenue
7.89
1.31
0.15
0
Total current liabilities
13.8
30.3
39
33.1
23.9
21.7
21.2
Lease liabilities
11.7
10.4
11.3
9.2
7.67
4.8
1.53
Other non-current liabilities
0.38
0.13
Total liabilities
29.3
45.3
50.6
42.8
59.4
99.1
35
Paid-in capital
1.42
395
487
503
578
589
695
Retained earnings
-66.2
-175
-303
-399
-487
-618
-642
Other comprehensive income
-0.12
-0.19
0.45
0.4
0.55
0.45
0.47
Shareholders' equity
-64.9
220
185
104
92.1
-29
53.5
Total equity
-64.9
220
185
104
92.1
-29
53.5
Total liabilities and equity
147
265
235
147
152
70.1
88.5
Shares outstanding
0.16
1.52
1.7
1.71
3
3.86
6.18
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-52.3
-109
-128
-96
-87.7
-131
-24.2
Depreciation and amortization
1.4
2.74
3.02
2.31
1.56
1.03
0.93
Stock-based compensation
0.75
2.98
13.5
14.7
12.7
8.45
5.04
Deferred income tax
0
0
0
0
0
0
Change in payables
0.39
-0.13
-0.31
1.72
-2.22
0.05
1.41
Cash from operations
-46.8
-74.3
-116
-79.4
-79
-80.7
-82.5
Capital expenditures
-2.79
-2.06
-0.89
-0.94
-0.02
-0.13
Purchases of investments
-60.4
-32.1
-2.7
-104
-0.01
-108
-165
Cash from investing
6.79
32.8
3.02
-26.3
45
-18.3
-37.8
Stock issued
0.49
0.26
0.02
Cash from financing
85.5
192
78.7
0.16
88.3
0.36
102
Net change in cash
45.6
151
-34
-106
54.3
-98.7
-18.7
Free cash flow
-49.6
-76.3
-117
-80.3
-79
-80.9
Interest paid
0.01
Income taxes paid
0
0.32
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.51 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-2,112.0%
Operating income / revenue.
EBITDA margin
-2,083.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-1,945.0%
Pre-tax income / revenue.
Net margin
-2,031.0%
Net income / revenue.
Operating cash flow margin
-2,518.0%
Cash from operations / revenue.
Return on equity (ROE)
-238.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-114.5%
Net income / average total assets.
Return on invested capital (ROIC)
-4,152.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
2,363.0%
Research and development expense / revenue.
Stock-based pay / revenue
149.8%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
29.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-39.5%
Revenue vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-19.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-24.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
26.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-15.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-19.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
57.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
79.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
90.2%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.19x
Current assets / current liabilities.
Quick ratio
2.05x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.07x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.36
Revenue / diluted weighted shares.
Operating cash flow per share
-$9.03
Cash from operations / diluted weighted shares.
Book value per share
$5.11
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
9.20x
Market cap / revenue.
P/B
1.08x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.08x
Market cap / tangible book value, when positive.
EV/Sales
1.08x
Enterprise value / revenue.
Earnings yield
-220.8%
Net income / market cap (the inverse of P/E).
What was Aligos Therapeutics, Inc.'s revenue in fiscal 2025?
Aligos Therapeutics, Inc. reported revenue of $2.2M for fiscal 2025, 39.5% lower than the year before.
Was Aligos Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $24.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.